Abstract
Immunotherapy by using immune checkpoint inhibitors is a revolutionary development in oncology. Medical imaging is also impacted by this new therapy, particularly nuclear medicine imaging (also called radionuclide imaging), which uses radioactive tracers to visualize metabolic functions. Our aim was to review the current applications of nuclear medicine imaging in immunotherapy, along with their limitations, and the perspectives offered by this imaging modality. Method: Articles describing the use of radionuclide imaging in immunotherapy were researched using PubMed by April 2019 and analyzed. Results: More than 5000 articles were analyzed, and nearly 100 of them were retained. Radionuclide imaging, notably 18F-FDG PET/CT, already has a major role in many cancers for pre-therapeutic and therapeutic evaluation, diagnoses of adverse effects, called immune-related adverse events (IrAE), and end-of-treatment evaluations. However, these current applications can be hindered by immunotherapy, notably due to atypical response patterns such as pseudoprogression, which is defined as an increase in the size of lesions, or the visualization of new lesions, followed by a response, and hyperprogression, which is an accelerated tumor growth rate after starting treatment. To overcome these difficulties, new opportunities are offered, particularly therapeutic evaluation criteria adapted to immunotherapy and immuno-PET allowing us to predict responses to immunotherapy. Moreover, some new technological solutions are also promising, such as radiomic analyses and body composition on associated anatomical images. However, more research has to be done, notably for the diagnosis of hyperprogression and pseudoprogression. Conclusion: Immunotherapy, by its major impact on cancer and by the new patterns generated on images, is revolutionary in the field of medical images. Nuclear medicine imaging is already established and will be able to help meet new challenges through its plasticity.
Highlights
Cancers are a proliferation of abnormal cells that can have the ability to disrupt the host’s adaptive immune response to avoid a control by tumoricidal attack [1]
Immunotherapy using immune checkpoint inhibitors (ICI)—notably anti-CTLA-4, anti-progressive disease (PD)-1, and anti-PDL-1 (PD1 ligand) antibodies—is a recent successful therapeutic approach that reactivates the immune system against cancers [2,3]
In a meta-analysis combining 19 studies involving 11,640 patients treated by ICI or other drugs, a team observed that a durable response occurred for 25% of the patients treated by ICI, which is a far better rate when compared to other drug classes (11%) [4]
Summary
Cancers are a proliferation of abnormal cells that can have the ability to disrupt the host’s adaptive immune response to avoid a control by tumoricidal attack [1]. This process can be overcome by immunotherapy, which aims to stimulate the body’s immune system against cancer cells. (programmed cell death protein-1), and anti-PDL-1 (PD1 ligand) antibodies—is a recent successful therapeutic approach that reactivates the immune system against cancers [2,3]. As the therapeutic approach of ICI is different from usual cytotoxic approaches—notably by generating inflammations rather than direct lysis—medical imaging has to be interpreted differently than when using cytotoxic chemotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
